Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain

This article was originally published here

Denali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases.

The deal includes Denali’s preclinical Alzheimer’s projects, among other undisclosed candidates, which make use of the company’s antibody transport vehicles, or ATVs, to penetrate the blood-brain barrier.

Get the full story at our sister site, Drug Delivery Business News.

The post Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply